TTNP : Summary for Titan Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Titan Pharmaceuticals, Inc. (TTNP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.15-0.10 (-2.35%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4.25
Bid4.15 x 400
Ask4.25 x 100
Day's Range4.15 - 4.40
52 Week Range2.90 - 8.74
Avg. Volume107,366
Market Cap87.98M
PE Ratio (TTM)16.53
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire8 days ago

    Braeburn Pharmaceuticals' Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services

    PRINCETON, N.J., Jan. 13, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System ...

  • Titan Pharmaceuticals, Inc.: Strong price momentum but will it sustain?
    Capital Cube16 days ago

    Titan Pharmaceuticals, Inc.: Strong price momentum but will it sustain?

    Categories: Yahoo Finance Titan Pharmaceuticals, Inc. relative valuation is NEUTRAL and it has a fundamental analysis score of 58. Our analysis is based on comparing Titan Pharmaceuticals, Inc. with the following peers – Vanda Pharmaceuticals Inc., MediciNova, Inc., Celldex Therapeutics, Inc., Neuralstem, Inc., DURECT Corporation, Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, BioDelivery Sciences International, Inc., Johnson & ... Read more (Read more...)

  • PR Newswire17 days ago

    Titan Pharmaceuticals Appoints Two New Board Members

    SOUTH SAN FRANCISCO, Calif., Jan. 4, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, today announced the appointment of two new members to its board of directors. Mr. Scott Smith, president of global inflammation and immunology at Celgene Corporation, and Dr. Rajinder Kumar, CEO of MeRaD Pharmaceutical Ltd., bring to Titan extensive product development and commercialization experience in the U.S., Europe and Asia. "We are very pleased to welcome Mr. Smith and Dr. Kumar to our board," said Titan Executive Chairman Dr. Marc Rubin.